Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
Jazz wants to expand its sleep portfolio, while Macrogenics hopes trial data will support its first new drug application.
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.